ERCC1 and cancer: A reasonable assumption is that the upregulated exon VIII‐deficient ERCC1 variant attenuates the excision repair capacity of ERCC1 and augments the susceptibility of cancer cells to cisplatin treatment.[33] As expected, SNRPA depletion markedly reduced the recruitment of XPF to ERCC1 (Figure 4l).